AsianScientist (Mar. 27, 2017) – The Innovation Network Corporation of Japan (INCJ), Takeda Pharmaceutical Company Limited, and Medipal Holdings Co. have agreed to jointly invest a total of 10 billion yen (~US$90 million) to establish Scohia Pharma, Inc., a fast track drug discovery company.
Following its launch within Takeda’s Shonan Research Center, Scohia Pharma will sign a license agreement with Takeda for eight of Takeda’s renal, metabolic and cardiovascular research and development projects, with the goal of initiating operations on April 1, 2017. Takeda researchers with a high level of expertise in and knowledge of these therapeutic areas will be involved in Scohia Pharma’s activities.
“The establishment of Scohia Pharma represents not only a business model that will allow a high level of expertise to be brought to bear over an extended period of time in the renal, metabolic, and cardiovascular therapeutic areas, but is also an early step in the creation of a research park that will allow Takeda’s Shonan Research Center to gather a wide variety of healthcare knowledge in one location,” said Dr. Andy Plump, Director, Chief Medical and Scientific Officer at Takeda.
“Scohia Pharma will allow world-class scientists to realize their full potential, and the creative forces that will be generated as a result will ensure that suffering patients will have access to new treatment options. Scohia Pharma will show a new business model to the Japanese business industry how large domestic pharmaceutical companies successfully spin off a venture company,” said Mr. Yoichi Okumura, who has been appointed as the CEO of Scohia Pharma.
———
Source: Takeda; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
